Xultophy(IDegLira) ,a combination of insulin degludec(Tresibar) and liraglutide(Victoza) is approved by European Commission for marketing in EU states .Xultophy once daily injection is indicated for treatment of adults with type 2 dieabetes mellitus . This drug improves glycaemic control in combination with oral glucose -lowering products.
when compared with insulin degludec ,Xultophy showed reduction in HbA1C of 1.9% with mean weight loss of 2.7 kg and also a low rate of hypoglycaemia.
Novo Nordisk, the developer of Xultophy(IDegLira) has submitted marketing authorisation with EU on may 31st of '13 and got approval in Switzerland on 12 september '14
Chemistry:
Insulin degludec:
Structure:Modified insulin with 1 single amino acid delted in comparison to human insulin and cojugated to hexadecanedioic acid via gamma-L-glutamyl spacer at amino acid Lysine at B29 position.
IUPAC name:B29N(epsilon)-omega-carboxypentadecanoyl-gamma-L-glutamyl desB30 human insulin
Mechanisam of Action(MOA): It forms multi hexamers in subcutaneous tissues by addition of hexadecanedioic acid to lysine at the B29 position .This results in in formation of a subcutaneous depot that results in slow insulin release in to systemic circulation.
Duration of action: It is ultra-long acting with duration which lasts up to 40 hours .
Liraglutide:
Molecular Formula:C17H265N43051
Molecular Weight:3751.202
MOA of Liraglutide:
1-Liraglutide increases intracellular cyclic AMP[cAMP] which leads to insulin release in presence of elevated glucose concentrations.This secretion subsides a s glucose concentrations decrease and approach euglycemia.
2-decreasing glucagon secretion in glucose dependent manner
3-delaying gastric emptying.
when compared with insulin degludec ,Xultophy showed reduction in HbA1C of 1.9% with mean weight loss of 2.7 kg and also a low rate of hypoglycaemia.
Novo Nordisk, the developer of Xultophy(IDegLira) has submitted marketing authorisation with EU on may 31st of '13 and got approval in Switzerland on 12 september '14
Chemistry:
Insulin degludec:
Structure:Modified insulin with 1 single amino acid delted in comparison to human insulin and cojugated to hexadecanedioic acid via gamma-L-glutamyl spacer at amino acid Lysine at B29 position.
IUPAC name:B29N(epsilon)-omega-carboxypentadecanoyl-gamma-L-glutamyl desB30 human insulin
Mechanisam of Action(MOA): It forms multi hexamers in subcutaneous tissues by addition of hexadecanedioic acid to lysine at the B29 position .This results in in formation of a subcutaneous depot that results in slow insulin release in to systemic circulation.
Duration of action: It is ultra-long acting with duration which lasts up to 40 hours .
Liraglutide:
Molecular Formula:C17H265N43051
Molecular Weight:3751.202
MOA of Liraglutide:
1-Liraglutide increases intracellular cyclic AMP[cAMP] which leads to insulin release in presence of elevated glucose concentrations.This secretion subsides a s glucose concentrations decrease and approach euglycemia.
2-decreasing glucagon secretion in glucose dependent manner
3-delaying gastric emptying.